+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06324357

Study of Oral Zongertinib Alone or With Other Treatments for Advanced HER2-Positive Metastatic Breast, Gastric, Gastroesophageal, Esophageal, or Colorectal Cancers

Led by Boehringer Ingelheim · Updated on 2026-10-28

910

Participants Needed

104

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating zongertinib, alone and combined with other treatments, for adults aged 18 and older who have various types of HER2-positive cancers that have spread and cannot be removed by surgery. This study focuses on patients whose tumors show HER2 abnormalities and who have not responded to prior treatments. The goal is to find a suitable dose of zongertinib that patients can tolerate well and to see if the treatment can shrink tumors. Participants receive treatment in cycles and are assigned to different groups. In Part 1, groups receive increasing doses of zongertinib combined with one of several other drugs, including trastuzumab deruxtecan, trastuzumab emtansine, trastuzumab with capecitabine, zanidatamab, or mFOLFOX6 chemotherapy. In Part 2, participants are randomly assigned to groups receiving different doses of zongertinib alone or with these treatments. Some groups also participate in an extension phase. The study is open-label and conducted at multiple centers. During the study, participants visit the study site regularly for tumor assessments using CT or MRI scans, health monitoring, and reporting of any side effects. Researchers track tumor size changes, dose-limiting toxicities within 21 days, and objective responses up to 50 months. Patient-reported outcomes and other safety and pharmacokinetic measurements are also collected. Participants remain under medical observation throughout the study, which may last several years.

CONDITIONS

Brief Title

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Research Team

B

Boehringer Ingelheim

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here